• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

CLDX [ Celldex Therapeutics Inc ]
Last Trade 27.55 Date 5/19/2021
Change % 0.63 % Price Change 0.17
Open 27.8 52 Week High 33.235
High 28.28 52 Week Low 2.33
Low 27.32 Type stock
Volume 278745 Average Volume 720058
Prev Close 27.38 Stock Exchange NASDAQ
Bid 15.55 Ask 34.87
Bid Size 5 Ask Size 13
1st Yr Estimated EPS Growth 0.0904 2nd Yr Estimated EPS Growth 0.04
2 Years Forward Earning Yield -0.057 2 Years Forward PE Ratio
2 Years EV/Forward EBIT -12.0436 2 Years EV/Forward EBITDA -12.0436
Book Value per Share 4.9014 Book Value Yield 0.179
Buy Back Yield CAPE Ratio
Cash Return -0.0529 Cash Flow per Share -1.3179
Cash Flow Yield -0.0481 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0625 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT -14.0478 EV / Forward EBITDA -14.0478
EV / Forward Revenue 202.6004 EV / Pre Tax Income
EV / Revenue 169.6189 EV / Total Asset 4.1618
Expected Dividend Growth Rate Free Cash Flow per Share -1.3714
Free Caash Flow Ratio Free Cash Flow Yield -0.0501
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.0548 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 5.586193 PB Ratio 10 Year Growth 0.112702
PB Ratio 3 Year Growth 1.49091 Cash Ratio 3 Year Average 185.655
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.902737
Price to Cash Ratio 6.159872 Price / EBITDA
Price to Sales Ratio 179.266411 Price to Sales Ratio 10 Year Growth 0.520212
Price to Sales Ratio 3 Year Avg 30.337592 Price to Sales Ratio 5 Year Avg
Sale per Share 0.1527 Sales Yield 0.0056
Sustainable Growth Rate -0.4584 Tangible Book Value per Share 4.1267
Tangible Book Value per Share 3 year Avg 4.8047 Tangible Book Value per Share 5 year Avg 8.8722
Total Asset per Share 5.5299 Total Yield
Working Capital per Share 4.1531 Working Capital per Share 3 Year Avg 5.4705
Working Capital per Share 5 Year Avg 10.6898 Beta 2.975512
Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders, and diseases caused by infectious organisms. Its precision targeted immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates, and immunomodulators to create disease-specific drug candidates. The company offers Rotarix for the treatment of rotavirus infection. Its clinical development programs include CDX-110, which is in Phase IIb clinical trail for the treatment of glioblastoma multiforme; CDX-011 that is in Phase II clinical trial to treat metastatic melanoma and breast cancer; and CDX-1307, a Phase I clinical trial product for treating colorectal, bladder, pancreas, ovarian, and breast tumors, as well as CDX-1401 and CDX-1135, which are in Phase I/II clinical trials for the treatment of multiple solid tumors and renal diseases respectively. The company?s preclinical product candidates comprise CDX-301 for treating cancer, and autoimmune diseases and transplants; CDX-1127 for immuno-modulation and multiple tumors; CDX-014 to treat renal and ovarian cancer; and CDX-1189 for renal diseases. It has collaborative partnership agreements with GlaxoSmithKline plc; Pfizer Inc.; Vaccine Technologies, Inc.; and TopoTarget A/S, as well as research collaboration and licensing agreements with Medarex, Inc.; Alteris Therapeutics, Inc.; 3M Company; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company was founded in 1983 and is headquartered in Needham, Massachusetts.